As a qui tam suit alleging fraud against one of the biggest private contractors for the multibillion-dollar Medicare Part D prescription-drug program heads toward discovery, a federal judge has defined the parameters for the discovery process.
U.S. District Senior Judge Ronald Buckwalter of the Eastern District of Pennsylvania weighed the 30 affirmative defenses raised by defendant CVS Caremark and the 19 dismissals sought by the plaintiff, Anthony Spay. Buckwalter granted a handful of Spay’s motions to dismiss and let stand nearly 12 challenged affirmative defenses.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
